GleamWall
中文EN

LABT Lakewood-Amedex Biotherapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2079272 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.7%
Debt / equity0.00x
Current ratio5.22x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
Cost of revenue——$507,292———
R&D expense$733,096$503,020$182,147$752,931$146,901$169,703
SG&A expense$776,476$3.29M$703,444$1.13M$489,325$371,747
Operating income-$1.51M-$3.79M-$886,750-$1.88M-$637,384-$542,609
Interest expense$0$10,633$38,219$37,808$23,949$1,315
Net income-$1.47M-$3.77M-$923,291-$1.91M-$655,943-$539,617
EBITDA-$1.51M-$3.79M-$885,591-$1.88M-$636,226-$541,450
EPS (basic)-0.62-2.75-0.20-3.46-1.66-0.15
EPS (diluted)-0.62-2.75-0.20-3.46-1.66-0.15
Weighted avg. shares (diluted)2.39M1.42M7.00M696,880694,4506.94M
Balance sheet
Cash & equivalents$2.82M$2.58M$11,709$658,410$1.27M$477,009
Short-term investments$500,000$2.00M————
Current assets$3.51M$4.85M$50,626———
PP&E, net$5,749$6,908$8,066———
Total assets$3.60M$4.96M$196,343———
Current liabilities$673,290$628,926$3.03M———
Total liabilities$673,290$628,926$3.04M———
Shareholders' equity$2.93M$4.33M-$2.84M-$1.27M-$683,251-$76,233
Shares outstanding3.66M2.17M7.04M———
Cash flow statement
Operating cash flow-$1.26M-$2.10M-$349,691-$610,045-$508,554-$404,089
Investing cash flow$1.50M—————
Financing cash flow$0$6.68M$125,000$0$1.30M$200,000
Depreciation & amortization$1,159$1,159$1,159$1,159$1,158$1,159
Stock-based compensation$68,777$61,246$46,180$1.20M$48,925$53,773

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.